Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chongqing Zhifei Biological Products Co., Ltd.
  6. News
  7. Summary
    300122   CNE100000V20

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

(300122)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-09-22
85.02 CNY   +3.91%
08/30Zhifei Biological's H1 Profit Tanks 32% as Costs Outweigh Revenue
MT
08/29Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/08Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on July 15, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Are Chinese COVID-19 shots effective against the Delta variant?

06/28/2021 | 11:55pm EDT

BEIJING, June 29 (Reuters) - Many countries from China to Indonesia and Brazil rely heavily on Chinese vaccines to inoculate their people against COVID-19, but there are growing concerns about whether they provide enough protection against the Delta variant, first identified in India.

Below are views from China's health experts about the effectiveness of home-grown vaccines against the Delta, which is becoming the globally dominant variant, and virus preventive measures China is taking.

DO CHINESE VACCINES WORK AGAINST DELTA?

China has not provided vaccine effectiveness results against the variant based on large-scale data in clinical trials or real-world use, nor offered detailed information from lab tests, but Chinese experts are urging people to get inoculated as soon as possible.

The lack of detailed data on the Chinese vaccines against the Delta has hobbled any meaningful peer reviews by foreign experts.

Researchers found that Chinese vaccines are somewhat effective in reducing the risk of symptomatic and severe cases caused by Delta, Zhong Nanshan, a epidemiologist who helped shape China's COVID-19 response, told reporters.

It is based on analysis of infections in Guangzhou city, and Zhong told Reuters the results are preliminary and the sample size is small.

Sinovac spokesman Liu Peicheng told Reuters preliminary results based on blood samples from those vaccinated with its shot showed a three-fold reduction in neutralizing effect against the Delta.

He said a booster shot following the two dose-based regimen could quickly elicit stronger and more durable antibody reaction against the Delta. However, he didn't provide detailed data.

Antibodies triggered by two Chinese vaccines are less effective against the Delta compared with other variants, Feng Zijian, former deputy director at the Chinese Center for Disease Control and Prevention, told state media last week.

Feng did not provide details including the name of the two vaccines.

The shots could still offer protection, since none of those vaccinated in southern Guangdong province, where China's first cases of the Delta variant were found, developed severe symptoms. All severe cases are from unvaccinated people.

Jin Dong-Yan, a virologist at the University of Hong Kong, said Feng's comment alone is not enough to back up the claim that Chinese vaccines are effective against severe cases, as more data is needed.

Indonesia, which has reported record daily cases recently due to a surge in the Delta variant, saw hundreds of medical workers infected by the COVID-19 despite being vaccinated with Sinovac's shot, officials said earlier this month.

It was not immediately clear, however, if the Indonesian medical workers were infected by the Delta variant.

HOW DO THEY COMPARE WITH WESTERN SHOTS?

A study by Public Health England (PHE) found in May the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the Delta two weeks after the second dose.

That compared with 93% effectiveness against the Alpha variant, first identified in Britain.

Two doses of the AstraZeneca vaccine were 60% effective against symptomatic disease from the Delta compared with 66% effectiveness against the Alpha, PHE said.

There is no substantial data showing how protective Johnson & Johnson's single-dose COVID-19 vaccine is, and U.S. infectious disease experts are weighing the need for booster shots using mRNA vaccines.

HOW SEVERE WAS THE GUANGDONG OUTBREAK?

Guangdong, China's major manufacturing and export hub, became the country's biggest cluster of Delta cases since reporting its first locally transmitted Delta variant infection in May.

The Delta infections included 146 cases in Guangdong's capital Guangzhou and several cases from the southern tech hub of Shenzhen and nearby Dongguan city.

No new domestic transmissions of any variant have been reported in the province from June 22.

WHAT CHINA HAS DONE?

Guangdong, which has 126 million people, has fast-tracked its vaccination effort since the outbreak. It had administered just 39.15 million doses as of May 19, but the number shot up to 101.12 million by June 20.

Guangzhou, Shenzhen and Dongguan quickly sealed off neighbourhoods where those who were infected and their contacts visited and launched multiple rounds of mass testing, following the protocols observed during previous outbreaks.

The cities also required those travelling out of the province to show proof of negative COVID-19 test results.

Zhong, the epidemiologist, said that without effective control measures 7.3 million people in Guangzhou city would have been infected in the first 20 to 30 days after the initial case. (Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim & Shri Navaratnam)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.83% 10016 Delayed Quote.15.42%
BIONTECH SE -1.27% 128.35 Delayed Quote.-50.21%
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 3.91% 85.02 End-of-day quote.-31.77%
EURO / BRAZILIAN REAL (EUR/BRL) 1.17% 5.0976 Delayed Quote.-20.56%
All news about CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
08/30Zhifei Biological's H1 Profit Tanks 32% as Costs Outweigh Revenue
MT
08/29Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Half Ye..
CI
07/08Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares for..
CI
06/21Some Omicron sub-variants escaping antibodies from Sinopharm shot -Chinese study
RE
05/23Chongqing Zhifei Biological Products Co., Ltd. Approves Cash Dividend for the Year 2021
CI
05/05UBS Adjusts Chongqing Zhifei Biological Products' Price Target to 163 Yuan From 175 Yua..
MT
04/28Zhifei Biological's Q1 Profit Surges 105% as Sales More Than Double
MT
04/28Chongqing Zhifei Biological Products Co., Ltd. Proposes Final Cash Dividend for the Yea..
CI
04/27Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the First Q..
CI
04/13Chongqing zhifei biological products co slumps more than 15%…
RE
More news
Analyst Recommendations on CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
More recommendations
Financials
Sales 2022 32 557 M 4 568 M 4 568 M
Net income 2022 7 607 M 1 067 M 1 067 M
Net cash 2022 8 170 M 1 146 M 1 146 M
P/E ratio 2022 18,0x
Yield 2022 1,12%
Capitalization 136 B 19 085 M 19 085 M
EV / Sales 2022 3,93x
EV / Sales 2023 3,23x
Nbr of Employees 5 077
Free-Float 14,7%
Chart CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Chongqing Zhifei Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 85,02 CNY
Average target price 130,28 CNY
Spread / Average Target 53,2%
EPS Revisions
Managers and Directors
Ren Sheng Jiang Chairman & General Manager
Zhen Jing Li Chief Financial Officer
Yu Qin Wu Chairman-Supervisory Board
Bao Kui Liu Independent Director
Gang Deng Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-31.77%19 085
CSL LIMITED-4.33%87 783
SAMSUNG BIOLOGICS CO.,LTD.-14.73%38 653
BIOGEN INC.-17.56%28 700
WUXI BIOLOGICS (CAYMAN) INC.-49.86%25 210
BIOMARIN PHARMACEUTICAL INC.-3.97%15 736